Peptron is a clinical-stage biotech that has no finished drug yet on the market. Its core technology is 'SmartDepot,' a long-acting drug-delivery platform that encapsulates a drug in microparticles to release it slowly in the body over one to six months, and it makes money through its own pipeline applying this to GLP-1-class obesity and diabetes or Parkinson's drugs and through licensing to global pharmaceutical companies. With 2025 annual revenue of only about ₩5.6 billion and continuing operating losses, the biggest focus is whether a SmartDepot platform technology evaluation agreement signed with Eli Lilly in October 2024 - whose evaluation period was extended by an agreement for additional in-vivo experiments - converts into a full contract. What stands out recently is that SmartDepot targets the real demand for dosing convenience in the GLP-1 market and has advanced to the evaluation-agreement stage with a world-class pharmaceutical company, and its short-term liquidity is ample. At the same time, it has no profit-generating product yet and is in its fifth year of operating losses, so its corporate value depends heavily on the single event of whether the Lilly evaluation succeeds.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue rose 78.8% year over year, and the pace is quickening (3-year trend: mixed).
- Most recent quarter (Q1 2026) revenue was 21.4% higher than a year earlier.
- ROE is -9.7% (total-net basis). It is below the sector average.
- Operating margin is -377.2%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Choi Ho-il 7.15% (individual)
Controlling bloc incl. related parties 8.47%
With the controlling bloc holding 8%, ownership is dispersed, leaving room for control-related or activist dynamics.
🔎 In-depth analysis
- Peptron is a clinical-stage biotech that has no finished drug yet generating sales profit, so the way it actually makes money is through early upfront and research-service income from transferring its own core technology to other pharmaceutical companies, plus small-scale product revenue.
- Its core asset is a long-acting drug-delivery platform called 'SmartDepot.' It is a technology that encapsulates a drug in a microparticle formulation to release it slowly in the body, sustaining the drug's effect for one month up to a maximum of six months, with the goal of reducing injections given daily or weekly to about once a month.
- The company has its own pipeline applying this platform to drugs such as GLP-1-class obesity and diabetes peptides and Parkinson's treatments, and at the same time it generates revenue by licensing the technology itself to global pharmaceutical companies.
- Annual revenue in 2025 was about ₩5.6 billion, small relative to the company's size, and with most of its resources going into R&D, operating losses continue.
- The recent closing price is ₩159,300 and the market capitalization is ₩3.7 trillion.
- The price sits below its 20-day moving average (₩196,210) and below its 60-day moving average (₩240,795).
- It trades below both its short-term and medium-term moving averages, so the trend is on the subdued side.
- The RSI (a supplementary indicator that gauges upward versus downward strength over the past 14 days on a 0-100 scale) is 35.0, a neutral level.
- The one-month change is -34.2%, the three-month change is -42.7%, and the position relative to the 52-week high is -58.7%.
- Relative strength versus the KOSDAQ is 50 (on a 1-99 scale, converted from returns against the index over the past year with more recent performance weighted more heavily; higher means stronger than the market).
- This places it in roughly the top 50% of all stocks by strength.
- Over the past three months it lagged the index by 23.0%.
- When reading the chart, it is best to consider trading volume together with the dates of disclosures.
- This is a typical clinical-stage biotech that is hard to value by earnings- or asset-based multiples.
- Because 2025 EPS (earnings per share) was -₩592.9, a loss, the P/E ratio (how many times one year's earnings the share price is) cannot be calculated, while the P/B ratio (how many times book shareholders' equity the share price is) is 26.16x and the P/S ratio (how many times revenue the share price is) is about 752x, both very high.
- Rather than meaning the company is expensive, this shows that its market value is priced on the future prospect of technology licensing, not on today's small revenue and book value.
- On profitability, ROE (how much is earned in a year on equity) of -9.7% and an operating margin of -377% show a large loss.
- That said, financial stability itself is not bad.
- The debt ratio (debt relative to equity) is 126%, but the current ratio (assets available for immediate use relative to debt due within a year) is very high at 16.4x, so short-term funding capacity is on the ample side.
- In other words, this should be understood not as overvalued simply because multiples are high, but as a structure in which the success of licensing determines the valuation.
- Revenue in 2025 was about ₩5.6 billion, up 78.8% year on year, and cumulative revenue in the first quarter of 2026 was about ₩1.97 billion, up 21.4% from the same period a year earlier.
- That said, over its five-year history (2021-2025) revenue itself swung widely, falling from the ₩6 billion range to the ₩3 billion range and then recovering, so this revenue growth is more accurately seen as volatility from the timing at which contract and research income is recognized.
- Operating losses continued throughout the five years (-₩21.2 billion in 2025), and net losses continued as well.
- Future earnings are hard to estimate by extending ordinary seasonality or recent quarterly results.
- The variable that would fundamentally change earnings is not its own results but whether the Eli Lilly platform evaluation agreement signed in October 2024 leads to a full-scale licensing or technology-transfer contract, and whether its own GLP-1 and Parkinson's pipeline advances clinically.
- Until this event materializes, the loss-making structure is likely to continue, so it is hard to estimate this year's net profit as a well-grounded positive figure.
- The most important flow is the SmartDepot platform collaboration with Eli Lilly.
- On October 7, 2024, the company signed a non-exclusive 'platform technology evaluation agreement' and began joint research applying SmartDepot to Lilly's peptide drugs, after which the two sides agreed to conduct additional in-vivo experiments, extending the evaluation period.
- Whether this evaluation leads to a full contract (a formal licensing or technology-transfer deal) is the company's biggest focus.
- Beyond that, disclosures such as regular IR events, the annual general meeting, and quarterly and business reports followed, but these are closer to routine procedures than events that materially change earnings.
- A point to watch is that an evaluation agreement is, after all, an 'evaluation' and does not guarantee a full contract, so depending on the result and timing, share-price volatility can be pronounced.
- The points to watch are clear.
- The strengths are that SmartDepot is a platform precisely targeting the real demand for 'dosing convenience (long-acting)' required in the obesity and diabetes GLP-1 market, that it has advanced to the evaluation-agreement stage with a world-class pharmaceutical company so that its technology is being validated, and that its short-term liquidity capacity is ample.
- On the other hand, the cautions are that it has no profit-generating product yet and is in its fifth year of operating losses, and that its corporate value depends heavily on the single event of whether the Lilly evaluation succeeds, rather than on earnings.
- In sum, if the evaluation leads to a full contract and a licensing-revenue structure opens up, there is room for a strong re-valuation, whereas if the evaluation is delayed or falls through, the grounds for supporting the current high multiples weaken.
- Rather than declaring it overvalued on earnings and P/B multiples alone, judging it by the progress of this event fits the nature of this stock.
🔎 Valuation vs peers Inconclusive
A comparison as a 'platform-type biotech' that licenses core technology to global pharmaceutical companies rather than being valued on revenue and profit; Alteogen (a subcutaneous-formulation hyaluronidase platform licensor) and LigaChem Biosciences (an ADC platform licensor) are the true comparison group by business structure, while Hugel, already a profit-generating finished-drug (toxin and filler) company, differs in character and serves only as a reference contrast.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Alteogen | 113.48x | 36.11x | 31.82% |
| LigaChem Biosciences | 0.00x | 8.62x | -18.04% |
| Hugel | 20.61x | 3.06x | 14.82% |
(a) The true comparison group is Alteogen and LigaChem Biosciences, which are valued on platform licensing rather than earnings. Peptron has no large full-contract revenue yet, so its P/B of 29.8x is lower than Alteogen's (43x), but its validation stage is too early to compare directly with Alteogen, whose licensing track record is established. (b) The P/B and P/S multiples are very high, but this results from future licensing expectations being pre-reflected against a small current revenue and book value, so the premium is of a clear character. (c) The 2025 loss makes the P/E impossible to derive, and future earnings hinge on the unconfirmed single event of whether the Lilly evaluation succeeds, so forward earnings cannot be estimated on a well-grounded basis. Therefore, without declaring it cheap or expensive, it is appropriate to leave it Inconclusive until whether the evaluation agreement converts into a full contract is confirmed.
Price history Close · MA20 · MA60
The latest close is ₩159,300 and the market capitalization is ₩3.7 trillion. The price sits below its 20-day moving average (₩196,210) and below its 60-day moving average (₩240,795). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 35.0, a neutral level. The one-month change is -34.2%, the three-month change is -42.7%, and the position relative to the 52-week high is -58.7%. Relative strength versus the KOSDAQ is 50 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 50% of all stocks. Over the past three months it lagged the index by 23.0%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -23.01% / 6M -24.49% / 12M -20.81%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 26.16x is above the sector median (1.37x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is -9.7%, below the sector average (3.0%). The operating margin is -377.2%. The debt ratio is 126.0%, so the financial structure is moderate.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $2.2M | $2.1M | $3.7M | +78.76% ↑ faster |
| Operating profit | -$10.5M | -$11.0M | -$14.1M | — |
| Net profit | -$10.6M | -$14.6M | -$9.2M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.4M | $3.9M | $2.2M | $2.1M | $3.7M |
| Operating profit | -$10.4M | -$10.1M | -$10.5M | -$11.0M | -$14.1M |
| Net profit | -$10.0M | -$10.0M | -$10.6M | -$14.6M | -$9.2M |
| Revenue CAGR | 4-yr avg -3.96% | ||||
Revenue rose 78.8% year over year (2023 ₩3.3 billion → 2024 ₩3.2 billion → 2025 ₩5.6 billion), and the three-year trend is 'mixed'. The pace of growth also quickened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 5 years on record, revenue compound annual growth (CAGR) is -4.0%. The two-year revenue CAGR is 29.8%. In the most recent quarter (Q1 2026), revenue was 21.4% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- Revenue grew 78.8% year over year, a sign of growth.
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2024-10-07FilingSigned a SmartDepot long-acting platform technology evaluation agreement (non-exclusive license) with Eli Lilly and began joint research targeting Lilly peptide drugsThe core trigger for the company's corporate value. Entering the technology-validation stage with a global pharmaceutical company provides grounds for expectations of platform credibility and licensing expansion, but as an evaluation stage it does not guarantee a full contract (the core of medium-term volatility) Source
- 2026-03-20IRHeld an investor briefing (IR) - explained the business status, pipeline, and progress of the platform collaborationA short-term information event. Affects market perceptions of the progress of the Lilly evaluation and of its own pipeline Source
- 2026-05-15EarningsFiled the Q1 2026 report - cumulative revenue about ₩1.97 billion (+21.4% YoY), operating loss about -₩5.78 billion, net loss about -₩6.11 billionConfirms the continuing loss-making structure. Revenue rose slightly but this is not a swing-to-profit event, and whether the licensing succeeds, rather than the results, determines the valuation Source
- 2026-03-18FilingFiled the 2025 business report - annual revenue about ₩5.63 billion (+78.8% YoY), operating loss about -₩21.26 billion, net loss about -₩13.82 billionRevenue recovered but confirms a five-year run of operating losses. Supports the view that it should be approached by platform and licensing value rather than earnings-based valuation Source
Figure cross-check computed ↔ external
Recent filings
- 2026-05-29OwnershipOwnership-change filing
- 2026-05-15PeriodicQuarterly report
- 2026-03-31OwnershipOwnership-change filing
- 2026-03-26Disclosure
- 2026-03-26Shareholders' meeting notice
- 2026-03-20Disclosure
- 2026-03-18PeriodicAnnual business report
- 2026-03-18Audit report
- 2026-03-10Amended filing
- 2026-03-10OwnershipOwnership-change filing
- 2026-03-09Disclosure
- 2026-03-09Shareholders' meeting notice
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.